Integrase strand inhibitors (INSTI) are the newest class of antiretroviral (ARV) therapies available to patients. There is little surveillance data on INSTI resistance, particularly in the South. A retrospective review on all patients who underwent PhenoSense Integrase testing between January 1, 2012 and June 30, 2013 was performed to better identify who should be screened for integrase strand transfer inhibitor (INSTI) resistance at the Interim Louisiana State University Hospital (ILH).
View Article and Find Full Text PDF